JPH08119829A - External medicine for skin - Google Patents
External medicine for skinInfo
- Publication number
- JPH08119829A JPH08119829A JP6281269A JP28126994A JPH08119829A JP H08119829 A JPH08119829 A JP H08119829A JP 6281269 A JP6281269 A JP 6281269A JP 28126994 A JP28126994 A JP 28126994A JP H08119829 A JPH08119829 A JP H08119829A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- acid
- effect
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、皮膚外用剤に関し、さ
らに詳しくは、皮膚の炎症、乾燥等を防止することがで
き、乾燥性皮膚疾患及びこれに準ずる皮膚症状を示すド
ライスキンに対して優れた効果をしめす皮膚外用剤に関
する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for skin, and more particularly to dry skin which can prevent skin irritation, dryness, etc., and exhibits dry skin diseases and skin symptoms similar thereto. The present invention relates to a skin external preparation exhibiting excellent effects.
【０００２】[0002]
【従来の技術】従来、皮膚の炎症、乾燥等を防止するた
めに用いられてきた薬効成分としては、アラントイン、
アロエ抽出物、胎盤抽出物、人参抽出物、ヒアルロン
酸、コラーゲン、アミノ酸類等が知られている。しかし
ながらこれらの薬剤成分を含む皮膚外用剤では、十分な
効果が得られることができず、より優れた作用を有する
皮膚外用剤の開発が望まれていた。2. Description of the Related Art Conventionally, allantoin is used as a medicinal component that has been used to prevent skin irritation, dryness, etc.
Aloe extract, placenta extract, ginseng extract, hyaluronic acid, collagen, amino acids and the like are known. However, a skin external preparation containing these drug components cannot obtain a sufficient effect, and development of a skin external preparation having more excellent action has been desired.
【０００３】一方、エゴマ油は、ω−３系高度不飽和脂
肪酸の一種であるα−リノレン酸を高度に含有してお
り、肌に塗布した場合、潤いを与え、肌のかさつきを防
ぐ効果が知られている。また、このα−リノレン酸は、
体内においてエイコサペンタエン酸やドコサヘキサエン
酸に代謝される。これらのω−３系高度不飽和脂肪酸
は、現在、制ガン効果やアレルギー反応をおこすロイコ
トリエンの産生を減少させる効果があることがわかり、
注目を集めている。On the other hand, perilla oil contains a large amount of α-linolenic acid, which is one of the ω-3 polyunsaturated fatty acids, and when applied to the skin, it has the effect of moisturizing and preventing the skin from becoming bulky. Are known. Also, this α-linolenic acid is
It is metabolized in the body to eicosapentaenoic acid and docosahexaenoic acid. These ω-3 polyunsaturated fatty acids are currently found to have an anti-cancer effect and an effect of reducing the production of leukotrienes that cause allergic reactions,
It is getting attention.
【０００４】[0004]
【発明が解決しようとする課題】本発明者等は、エゴマ
油の有する上記作用に着目し、これを皮膚外用剤、特に
皮膚の炎症、乾燥等の改善作用を有する皮膚外用剤に配
合することを試みた。しかし、エゴマ油を単独に配合し
た場合の皮膚の炎症、乾燥等の改善作用は十分なものと
はいえず、また他の基剤等の影響により、これの本来有
する効果が十分に発揮されえないのが実情であった。DISCLOSURE OF THE INVENTION The present inventors have focused on the above-mentioned action of perilla oil and blended it into a skin external preparation, particularly a skin external preparation having an improving effect on skin inflammation, dryness and the like. Tried. However, the effect of improving skin irritation, dryness, etc. when the sesame oil is blended alone is not sufficient, and due to the influence of other bases etc., the inherent effect of this may not be fully exerted. It was the reality.
【０００５】更に、より高い効果を得る目的で、エゴマ
油を高濃度で配合した場合の作用効果にも限界があり、
逆に、これら化合物自体の有する特有の色や臭いの発生
により、配合量や剤型等製品面における制限も生じてく
るといった問題もあった。Further, there is a limit to the action and effect when the perilla oil is blended at a high concentration for the purpose of obtaining a higher effect.
On the contrary, there is also a problem that due to the generation of the unique color and odor of these compounds themselves, there are restrictions on the amount of formulation, formulation, etc. in terms of products.
【０００６】[0006]
【課題を解決するための手段】前記実情に鑑み、本発明
者等は、エゴマ油の有する作用を十分に引き出すべく鋭
意研究を行った。そしてその結果、これらと特定の化合
物とを組み合わせることにより、優れた皮膚の炎症、乾
燥等の改善作用が安定かつ相乗的に発揮されることを見
いだし本発明を完成するに至った。In view of the above circumstances, the inventors of the present invention have conducted earnest studies to sufficiently bring out the action of perilla oil. As a result, they have found that, by combining these with a specific compound, excellent effects of improving skin inflammation, dryness and the like are exhibited stably and synergistically, and the present invention has been completed.
【０００７】すなわち本発明は、（ａ）成分及び（ｂ）
成分 （ａ）エゴマ油 （ｂ）グリチルリチン酸、グリチルレチン酸、リン脂
質、水添リン脂質、コレステロール及びその誘導体並び
にそれらの塩、シソ抽出物、ドクダミ抽出物、ユキノシ
タ抽出物、マルチトール、ソルビトール、マンニトール
から選ばれる１種または２種以上を含有する皮膚外用剤
を提供するものである。That is, the present invention provides the components (a) and (b)
Component (a) Perilla oil (b) Glycyrrhizic acid, glycyrrhetinic acid, phospholipids, hydrogenated phospholipids, cholesterol and its derivatives and salts thereof, perilla extract, Dokudami extract, Yukinoshita extract, maltitol, sorbitol, mannitol An external preparation for skin containing one or more selected from the following.
【０００８】本発明において必須に使用される（ａ）成
分であるエゴマ油とは、エゴマＰｅｒｉｌｌａ ｆｒｕ
ｔｅｓｃｅｎｓ Ｂｒｉｔｔｏｎ ｖａｒ．ｊａｐｏｎ
ｉｃａ Ｈａｒａ及びその他同属植物（シソ科）の種子
から通常用いられる方法により抽出されたものであり、
方法は特に限定されない。また、主成分であるα−リノ
レン酸をさらに濃縮して含量を高めたものや、あるいは
これら他の成分を調合した油脂組成物も含まれる。In the present invention, the sesame oil which is the component (a) that is essential is the sesame oil Perilla fru.
tescens Britton var. Japan
ica Hara and other homologous plants (Lamiaceae) extracted by a method usually used,
The method is not particularly limited. Further, it also includes a composition in which α-linolenic acid as a main component is further concentrated to increase the content, or an oil and fat composition prepared by mixing these other components.
【０００９】エゴマ油は、そのまま本発明の皮膚外用剤
に配合しても、また、更に水蒸気蒸留、活性炭処理、酸
性白土処理等によって精製したものを利用しても良い。The perilla oil may be blended as it is with the external preparation for skin of the present invention, or may be further refined by steam distillation, activated carbon treatment, acid clay treatment or the like.
【００１０】本発明の化粧料におけるエゴマ油の含有量
は、０．０００１〜１０重量％（以下単に「％」で示
す）であり、より好ましくは、０．０１〜５％である。
含有量が０．０００１％未満であると十分な効果か得ら
れないことがあり、また、１０％を超えて配合してもそ
れ以上の効果の増大は見られず、かえって着色、臭いの
発生や、剤型によっては沈殿が生じる等、製品面での問
題が生じる場合がある。The content of perilla oil in the cosmetic of the present invention is 0.0001 to 10% by weight (hereinafter simply referred to as "%"), and more preferably 0.01 to 5%.
If the content is less than 0.0001%, a sufficient effect may not be obtained, and if the content exceeds 10%, no further increase in the effect is seen, and rather, coloring and odor are generated. Also, depending on the dosage form, problems such as precipitation may occur on the product side.
【００１１】一方、本発明において他の必須成分である
（ｂ）成分は、グリチルリチン酸、グリチルレチン酸、
リン脂質、水添リン脂質、コレステロール及びその誘導
体並びにそれらの塩、シソ抽出物、ドクダミ抽出物、ユ
キノシタ抽出物、マルチトール、ソルビトール、マンニ
トールから選ばれる１種または２種以上である。On the other hand, the other essential component (b) in the present invention is glycyrrhizic acid, glycyrrhetinic acid,
One or more selected from phospholipids, hydrogenated phospholipids, cholesterol and its derivatives and salts thereof, perilla extract, dokudami extract, yukinoshita extract, maltitol, sorbitol, mannitol.
【００１２】これらの（ｂ）成分は、従来皮膚外用剤に
配合されている成分であり、その起源や取得方法は特に
限定されるものでなく、一般に市販されているものが使
用できる。These components (b) are components that have been conventionally compounded in external preparations for skin, and the origin and acquisition method thereof are not particularly limited, and generally commercially available ones can be used.
【００１３】上記の特定成分の本発明の皮膚外用剤にお
ける含有量（抽出物に関しては乾燥固形成として）０．
００００１〜１０％であり、より好ましくは０．００１
〜３％である。これら特定成分の含有量が０．００００
１％より少ない場合には十分な効果が得られないことが
あり、また、１０％を超えて配合してもそれ以上の効果
の増大は見られずかえって製剤面での悪影響が生ずる場
合がある。Content of the above-mentioned specific components in the external preparation for skin of the present invention (as an extract is a dry solid form).
00001 to 10%, more preferably 0.001
~ 3%. The content of these specific components is 0.0000
If it is less than 1%, a sufficient effect may not be obtained, and if it exceeds 10%, no further increase in effect may be seen, which may adversely affect the formulation. .
【００１４】更に、本発明の皮膚外用剤には、本発明の
効果を損なわない範囲で、前記必須成分の他に、通常の
皮膚外用剤に用いられる水性成分、粉体、界面活性剤、
油剤、保湿剤、アルコール類、ｐＨ調整剤、防腐剤、色
素、酸化防止剤、紫外線吸収剤、増粘剤、香料、美容成
分等を必要に応じて適宜配合することができる。Further, the external preparation for skin of the present invention contains, in addition to the above-mentioned essential components, an aqueous component, a powder, a surfactant, which is used in ordinary external preparations for skin, within a range that does not impair the effects of the present invention.
Oil agents, humectants, alcohols, pH adjusters, preservatives, pigments, antioxidants, ultraviolet absorbers, thickeners, fragrances, cosmetic ingredients and the like can be appropriately added as necessary.
【００１５】本発明の皮膚外用剤は（ａ）成分と（ｂ）
成分とを配合し、常法に従って製造することができ、乳
液、クリーム、化粧水、美容液、クレンジング、パッ
ク、洗浄料、ファンデーション等の化粧品の他、分散
液、軟膏剤、クリーム剤、外用液剤等の医薬品、医薬部
外品などとすることができる。The external preparation for skin of the present invention comprises (a) component and (b)
In addition to cosmetics such as emulsions, creams, lotions, beauty essences, cleansing, packs, detergents, foundations, etc., they can be mixed with the ingredients and produced according to a conventional method, as well as dispersions, ointments, creams, liquids for external use. And the like, and quasi-drugs.
【００１６】[0016]
【実施例】次に実施例を挙げて本発明をさらに説明する
が、本発明はこれらに限定されるものではない。EXAMPLES The present invention will be further described with reference to examples, but the present invention is not limited thereto.
【００１７】実施例１：乳液 以下に示す処方及び製法により、乳液を製造した。得ら
れた各乳液について、カラゲン足蹠浮腫抑制試験による
評価を行った。Example 1 Emulsion An emulsion was prepared by the following formulation and production method. Each of the obtained emulsions was evaluated by a carrageen footpad edema inhibition test.
【００１８】（処方）(Prescription)
【表１】 [Table 1]
【００１９】（製法） Ａ．成分（６）、（８）〜（１２）及び（１６）を加熱
混合し、７０℃に保つ。 Ｂ．成分（１）〜（５）、（７）及び（１３）、（１
４）を加熱混合し、７０℃に保つ。 Ｃ．上記Ｂを先のＡに加えて混合し、（１５）を加えて
均一に乳化し、３０℃まで冷却して乳液を得る。(Production Method) A. Ingredients (6), (8)-(12) and (16) are mixed by heating and kept at 70 ° C. B. Components (1) to (5), (7) and (13), (1
4) is heated and mixed, and kept at 70 ° C. C. The above B is added to the above A and mixed, (15) is added to uniformly emulsify, and the mixture is cooled to 30 ° C. to obtain an emulsion.
【００２０】（評価） カラゲニン足蹠浮腫抑制試験：６〜７週令のＷｉｓｔａ
ｒ系雄性ラットを１群１０匹とし、起炎剤として１％カ
ラゲニン生理食塩水溶液をラット後肢足蹠に皮下注射し
て浮腫を生じさせる、カラゲニン注射の２時間及び注射
直後にそれぞれの試料を０．１ｍｌずつ塗布し、カラゲ
ニン注射の４時間後の足蹠容積を測定し、対照群に対す
る浮腫抑制率を求める。(Evaluation) Carrageenin footpad edema suppression test: 6 to 7 weeks old of Vista
1 group of 10 r-type male rats was subcutaneously injected into the rat hind footpad with a 1% carrageenin physiological saline solution as an inflammatory agent to cause edema. 2 hours after carrageenin injection and immediately after injection 1 ml each was applied, and the footpad volume was measured 4 hours after the injection of carrageenin, and the edema inhibition rate relative to the control group was determined.
【００２１】カラゲニン足蹠浮腫抑制試験結果を表２に
示す。Table 2 shows the results of the carrageenin footpad edema inhibition test.
【００２２】[0022]
【表２】 [Table 2]
【００２３】表２の結果から明らかなごとく、エゴマ油
とグリチルリチン酸ジカリウム、シソ抽出物、ユキノシ
タ抽出物を併用した本発明品の１〜４は、それぞれを単
独で配合した比較品の１〜５に比較して、顕著な浮腫抑
制作用を示し、優れた消炎効果があることがわかる。As is clear from the results shown in Table 2, 1 to 4 of the products of the present invention in which perilla oil and dipotassium glycyrrhizinate, perilla extract, and Yukinoshita extract were used in combination were 1 to 5 of the comparative products in which they were blended alone. Compared with the above, it shows a remarkable edema inhibitory action and has an excellent anti-inflammatory effect.
【００２４】実施例２：乳液 以下に示す処方及び製法により、乳液を製造した。得ら
れた各乳液について、肌荒れ改善試験による評価を行っ
た。Example 2 Emulsion An emulsion was prepared by the following formulation and production method. The obtained emulsions were evaluated by a rough skin improvement test.
【００２５】（処方）(Prescription)
【表３】 [Table 3]
【００２６】（製法） Ａ．成分（６）、（８）〜（１０）及び（１４）を加熱
混合し、７０℃に保つ。 Ｂ．成分（１）〜（５）、（７）及び（１１）、（１
２）を加熱混合し、７０℃に保つ。 Ｃ．上記Ｂを先のＡに加えて混合し、（１３）を加えて
均一に乳化し、３０℃まで冷却して乳液を得る。(Production Method) A. The components (6), (8) to (10) and (14) are mixed by heating and kept at 70 ° C. B. Components (1) to (5), (7) and (11), (1
2) is mixed by heating and kept at 70 ° C. C. The above B is added to the above A and mixed, (13) is added to uniformly emulsify, and the emulsion is obtained by cooling to 30 ° C.
【００２７】（評価） 肌荒れ改善試験：２４才から４０才の健常人１０名をパ
ネルとし、実験的な荒れ肌を惹起する前の肌状態をミク
ロスコープカメラで撮影し、下記基準によりそのスコア
を求めた。実験的な荒れ肌は、上腕屈側部をエーテル、
アセトン（１：１）混液で処理することにより惹起し
た。さらにその後は７日間にわたって毎日朝と夜の２回
被験乳液を塗布し、荒れ肌惹起の３、５及び７日後に前
記と同様肌状態のスコアを求めた。(Evaluation) Rough skin improvement test: A panel of 10 healthy persons aged 24 to 40 was used to photograph the skin condition before experimental rough skin was induced with a microscopic camera, and the score was calculated according to the following criteria. It was Experimental rough skin, ether on the flexion of the upper arm,
It was caused by treatment with a mixed solution of acetone (1: 1). Further, thereafter, the test emulsion was applied twice daily in the morning and at night for 7 days, and the skin condition score was obtained 3, 5 and 7 days after the induction of rough skin.
【００２８】（基準） スコア １ 皮溝が不鮮明であり、角質の剥離が多く認められ
る。 ２ 皮溝がやや不鮮明であり、角質の剥離が認められ
る。 ３ 皮溝は認められるが浅いかまたは一方向性が強
い。 ４ 皮溝が認められやや網目状である。 ５ 網目状に整った皮溝が認められる。(Reference) Score 1 The skin groove is not clear, and many exfoliations of the keratin are observed. 2 The skin groove is slightly unclear, and exfoliation of the keratin is observed. 3 Defects are visible but shallow or unidirectional. 4 Skin groove is recognized and it is somewhat mesh-like. 5 Ridges arranged in a mesh pattern are recognized.
【００２９】肌荒れ改善試験結果を表４に示す。Table 4 shows the results of the rough skin improvement test.
【００３０】[0030]
【表４】 [Table 4]
【００３１】表４の結果から明らかな如く、エゴマ油と
マルチトール及び水添大豆リン脂質を併用した本発明品
５、６は、それぞれを単独で配合した比較品６〜８及び
これらを含まない比較品９に比較して、顕著な肌荒れ改
善効果作用を示し、優れた効果があることがわかる。As is clear from the results shown in Table 4, the products 5 and 6 of the present invention in which the perilla oil was used in combination with maltitol and hydrogenated soybean phospholipid did not contain the comparative products 6 to 8 in which each of them was blended alone, and these products Compared with Comparative product 9, it shows a remarkable effect of improving skin roughness, and it is understood that there is an excellent effect.
【００３２】実施例３：乳液 以下に示す処方及び製法により、乳液を製造した。得ら
れた乳液について、美肌効果を評価した。Example 3: Emulsion An emulsion was prepared by the following formulation and production method. The skin-cleansing effect of the obtained emulsion was evaluated.
【００３３】（処方） 本発明品１（実施例１に示すとおり） 本発明品６（実施例２に示すとおり） 比較品１（実施例１に示すとおり） 比較品２（実施例１に示すとおり） 比較品３（実施例１に示すとおり）(Prescription) Invention product 1 (as shown in Example 1) Invention product 6 (as shown in Example 2) Comparative product 1 (as shown in Example 1) Comparative product 2 (as shown in Example 1) Comparative product 3 (as shown in Example 1)
【００３４】（製法）それぞれ実施例１もしくは実施例
２に示した通り。(Production method) As described in Example 1 or Example 2, respectively.
【００３５】（評価） 美肌効果試験：顔面の皮膚がドライスキンであると認め
られる２５〜５６才の女性１５名をパネルとし、毎日朝
と夜の２回、８週間にわたって、洗顔後に適量の被験乳
液を顔面に塗布するように指示した。塗布による効果を
下の基準にしたがって評価した。(Evaluation) Skin beautification test: A panel of 15 women aged 25 to 56, whose skin on the face was recognized to be dry skin, was tested twice daily in the morning and evening for 8 weeks, and an appropriate amount of test was conducted after washing the face. Instructed to apply the emulsion to the face. The effect of coating was evaluated according to the criteria below.
【００３６】（基準） 評価 皮膚の乾燥が著しく改善され、肌の潤い、つ
やが出てきた。 著効 皮膚の乾燥が改善され、肌の潤いが感じられ
るようになった。 やや有効 皮膚の乾燥が目立たなくなった。 無効 使用前と変わらない。(Standard) Evaluation The dryness of the skin was remarkably improved, and the skin became moist and shiny. Remarkable effect The dryness of the skin was improved and the skin became moisturized. Somewhat effective Dryness of the skin is less noticeable. Disabled Same as before use.
【００３７】美肌効果試験結果を表５に示す。The results of the skin beautifying effect test are shown in Table 5.
【００３８】[0038]
【表５】 [Table 5]
【００３９】表５の結果から明らかな如く、エゴマ油と
グリチルリチン酸ジカリウム及び水添大豆リン脂質を併
用した本発明品１、２は、それぞれを単独で配合した比
較品１〜３に比較して、顕著なドライスキンの改善効果
を示し、優れた効果があることがわかる。As is clear from the results shown in Table 5, the products 1 and 2 of the present invention in which perilla oil, dipotassium glycyrrhizinate, and hydrogenated soybean phospholipid were used in combination were compared with Comparative products 1 to 3 in which each of them was blended alone. It shows a remarkable improvement effect on dry skin, and it can be seen that there is an excellent effect.
【００４０】実施例４：化粧水 次に示す処方及び下記製法で化粧水を得た。本発明の化
粧水は皮膚の炎症、乾燥等に対し優れた改善効果を有す
るものであった。Example 4: Lotion A lotion was obtained by the following formulation and the following production method. The lotion of the present invention had an excellent effect of improving skin irritation and dryness.
【００４１】 （処方） （重量％） （１）グリセリン ５．０ （２）１，３−ブチレングリコール ６．５ （３）ポリオキシエチレンソルビタン １．２ モノラウリン酸エステル（２０Ｅ．Ｏ．） （４）エチルアルコール ８．０ （５）エゴマ油 ０．０１ （６）シソ抽出液（注） ３．０ （７）防腐剤 ０．２ （８）香料 ０．１ （９）精製水 残量 （注）日光ケミカルズ社製(Formulation) (% by weight) (1) Glycerin 5.0 (2) 1,3-butylene glycol 6.5 (3) Polyoxyethylene sorbitan 1.2 Monolauric acid ester (20EO) (4) ) Ethyl alcohol 8.0 (5) Perilla oil 0.01 (6) Perilla extract (Note) 3.0 (7) Preservative 0.2 (8) Perfume 0.1 (9) Purified water Remaining amount (Note) ) Nikko Chemicals
【００４２】（製法） Ａ．（３）〜（５）、（７）及び（８）を混合溶解す
る。 Ｂ．（１）〜（２）、（６）及び（９）を混合溶解す
る。 Ｃ．上記ＡとＢを混合して均一にし、化粧水を得る。(Production Method) A. (3) to (5), (7) and (8) are mixed and dissolved. B. (1)-(2), (6) and (9) are mixed and dissolved. C. The above A and B are mixed and made uniform to obtain a lotion.
【００４３】実施例５：パック 次に示す処方及び下記製法でパックを得た。本発明のパ
ックは皮膚の炎症、乾燥等に対し優れた改善効果を有す
るものであった。Example 5: Pack A pack was obtained by the following formulation and the following production method. The pack of the present invention had an excellent effect of improving skin irritation and dryness.
【００４４】 （処方） （重量％） （１）ポリビニルアルコール ２０．０ （２）グリセリン ５．０ （３）カオリン ６．０ （４）ソルビトール（注） ０．０１ （５）エチルアルコール ２０．０ （６）エゴマ油 ０．０５ （７）防腐剤 ０．２ （８）香料 ０．１ （９）精製水 残量 （注）和光純薬社製(Formulation) (wt%) (1) Polyvinyl alcohol 20.0 (2) Glycerin 5.0 (3) Kaolin 6.0 (4) Sorbitol (Note) 0.01 (5) Ethyl alcohol 20.0 (6) Perilla oil 0.05 (7) Preservative 0.2 (8) Perfume 0.1 (9) Purified water balance (Note) Wako Pure Chemical Industries
【００４５】（製法） Ａ．成分（１）〜（４）及び（９）を混合し、７０℃に
加熱して攪拌する。 Ｂ．成分（５）〜（８）を混合する。 Ｃ．上記Ｂを先のＡに加え混合した後、冷却してパック
を得る。(Production Method) A. The components (1) to (4) and (9) are mixed, heated to 70 ° C. and stirred. B. Mix components (5)-(8). C. The above B is added to the above A, mixed and cooled to obtain a pack.
【００４６】実施例６：洗浄料 次に示す処方及び下記製法で洗浄料を得た。本発明の洗
浄料は皮膚の炎症、乾燥等に対し優れた改善効果を有す
るものであった。Example 6 Cleaning Agent A cleaning agent was obtained by the following formulation and the following production method. The cleansing agent of the present invention had an excellent effect of improving skin irritation and dryness.
【００４７】 （処方） （重量％） （１）ステアリン酸 １０．０ （２）パルミチン酸 ８．０ （３）ミリスチン酸 １２．０ （４）ラウリン酸 ４．０ （５）オレイルアルコール １．５ （６）精製ラノリン １．０ （７）香料 ０．１ （８）防腐剤 ０．２ （９）グリセリン １８．０ （１０）水酸化カリウム ６．０ （１１）エゴマ油 ０．５ （１２）グリチルレチン酸ステアリル（注） ０．０５ （１３）精製水 残量 （注）丸善製薬社製(Formulation) (% by weight) (1) Stearic acid 10.0 (2) Palmitic acid 8.0 (3) Myristic acid 12.0 (4) Lauric acid 4.0 (5) Oleyl alcohol 1.5 (6) Purified lanolin 1.0 (7) Perfume 0.1 (8) Preservative 0.2 (9) Glycerin 18.0 (10) Potassium hydroxide 6.0 (11) Perilla oil 0.5 (12) Stearyl glycyrrhetinate (Note) 0.05 (13) Purified water Remaining amount (Note) Maruzen Pharmaceutical Co., Ltd.
【００４８】（製法） Ａ．成分（９）〜（１０）及び（１３）を混合し、７０
℃に加熱する。 Ｂ．成分（１）〜（６）、（８）、（１１）及び（１
２）を混合し、７０℃に加熱する。 Ｃ．上記Ｂを先のＡに加え、暫く７０℃に保ち、けん化
反応が終了後、５０℃まで冷却し、（７）を加え、冷却
して洗浄料を得る。(Production Method) A. Mixing components (9)-(10) and (13), 70
Heat to ° C. B. Components (1) to (6), (8), (11) and (1
2) are mixed and heated to 70 ° C. C. The above B is added to the above A, and the temperature is maintained at 70 ° C. for a while, and after the saponification reaction is completed, it is cooled to 50 ° C., (7) is added, and cooled to obtain a cleaning agent.
【００４９】[0049]
【発明の効果】本発明の皮膚外用剤は、皮膚の炎症、乾
燥等を防止することができ、乾燥性疾患及びこれに準ず
る症状を示すいわゆるドライスキンに対して優れた改善
効果を示すものである。 以 上INDUSTRIAL APPLICABILITY The external preparation for skin of the present invention can prevent skin irritation, dryness and the like, and exhibits an excellent improving effect on so-called dry skin which shows dryness disease and symptoms similar thereto. is there. that's all
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 7/00 Ｇ 7/48 31/045 9455−4Ｃ 31/575 31/705 ＡＧＡ 35/78 ＡＢＥ Ｑ 8217−4Ｃ ＡＤＡ Ｃ 8217−4Ｃ 38/00 //(Ａ６１Ｋ 35/78 31:045） (Ａ６１Ｋ 35/78 31:705） ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display area A61K 7/00 G 7/48 31/045 9455-4C 31/575 31/705 AGA 35/78 ABE Q 8217-4C ADA C 8217-4C 38/00 // (A61K 35/78 31: 045) (A61K 35/78 31: 705)
Claims (1)
質、水添リン脂質、コレステロール及びその誘導体並び
にそれらの塩、シソ抽出物、ドクダミ抽出物、ユキノシ
タ抽出物、マルチトール、ソルビトール、マンニトール
から選ばれる１種または２種以上を含有することを特徴
とする皮膚外用剤。1. Components (a) and (b) (a) Perilla oil (b) Glycyrrhizic acid, glycyrrhetinic acid, phospholipids, hydrogenated phospholipids, cholesterol and its derivatives, and salts thereof, perilla extract, Dokudami A skin external preparation characterized by containing one or more selected from the group consisting of extract, Yukinoshita extract, maltitol, sorbitol and mannitol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP28126994A JP3513861B2 (en) | 1994-10-20 | 1994-10-20 | External preparation for skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP28126994A JP3513861B2 (en) | 1994-10-20 | 1994-10-20 | External preparation for skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08119829A true JPH08119829A (en) | 1996-05-14 |
| JP3513861B2 JP3513861B2 (en) | 2004-03-31 |
Family
ID=17636723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP28126994A Expired - Lifetime JP3513861B2 (en) | 1994-10-20 | 1994-10-20 | External preparation for skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3513861B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10218796A (en) * | 1997-02-07 | 1998-08-18 | Yoshiaki Honda | Percutaneous absorbefacient and skin preparation for external use containing the same |
| JP2001081008A (en) * | 1999-07-15 | 2001-03-27 | Shiseido Co Ltd | Skin preparation for external use keeping and improving the skin from chapping |
| JP2002212026A (en) * | 2001-01-18 | 2002-07-31 | Oriza Yuka Kk | Skin care preparation for beautifying skin |
| EP1265583A1 (en) * | 2000-03-07 | 2002-12-18 | Avon Products, Inc. | Method of treating skin conditions |
| WO2002102396A1 (en) * | 2001-06-15 | 2002-12-27 | Kyowa Hakko Kogyo Co., Ltd. | Preventives or remedies for arthritis |
-
1994
- 1994-10-20 JP JP28126994A patent/JP3513861B2/en not_active Expired - Lifetime
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10218796A (en) * | 1997-02-07 | 1998-08-18 | Yoshiaki Honda | Percutaneous absorbefacient and skin preparation for external use containing the same |
| JP2001081008A (en) * | 1999-07-15 | 2001-03-27 | Shiseido Co Ltd | Skin preparation for external use keeping and improving the skin from chapping |
| EP1265583A1 (en) * | 2000-03-07 | 2002-12-18 | Avon Products, Inc. | Method of treating skin conditions |
| EP1265583A4 (en) * | 2000-03-07 | 2003-06-11 | Avon Prod Inc | Method of treating skin conditions |
| US7736661B1 (en) * | 2000-03-07 | 2010-06-15 | Avon Products, Inc | Method of treating skin conditions |
| JP2002212026A (en) * | 2001-01-18 | 2002-07-31 | Oriza Yuka Kk | Skin care preparation for beautifying skin |
| WO2002102396A1 (en) * | 2001-06-15 | 2002-12-27 | Kyowa Hakko Kogyo Co., Ltd. | Preventives or remedies for arthritis |
| KR100887854B1 (en) * | 2001-06-15 | 2009-03-09 | 교와 핫꼬 기린 가부시키가이샤 | Preventives or Remedies for Arthritis |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3513861B2 (en) | 2004-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3696271B2 (en) | Whitening cosmetics | |
| EP1216696B1 (en) | Method for reducing the appearance of dark circles under the eyes | |
| JPH07196469A (en) | Cosmetics composition for care of composite skin | |
| WO2010089566A2 (en) | Composition for treatment of skin | |
| JPH07277939A (en) | Skin external preparation | |
| EP1172084A2 (en) | Cosmetic and dermatologic composition to eliminate sebum | |
| JPH11193207A (en) | Preparation for external use for skin | |
| JP2001081008A (en) | Skin preparation for external use keeping and improving the skin from chapping | |
| JP3758794B2 (en) | Collagen production promoter and anti-aging skin external preparation containing the same | |
| CA2365660A1 (en) | Treatment for skin | |
| JPH10203955A (en) | Antimicrobial low-irritating cosmetic | |
| JP2002003358A (en) | Skin care preparation | |
| JP2005047910A (en) | Sebum secretion-inhibiting composition | |
| JPH0867621A (en) | Skin activator having glycosaminoglycan production-accelerating action | |
| JPH08119829A (en) | External medicine for skin | |
| JP3507635B2 (en) | Composition suitable for external use | |
| JP3170700B2 (en) | Cosmetic for preventing skin aging | |
| JP2000344697A (en) | Long-chain branched alcohol and cosmetic and external preparation produced by using the alcohol | |
| KR20220001161A (en) | Composition for skin protection, including extracts derived from natural products | |
| JPH11302147A (en) | Cosmetic | |
| JP3197936B2 (en) | Cosmetics | |
| JPH09124500A (en) | Therapeutic agent for atopic dermatitis | |
| JP2001031554A (en) | Preparation for external use for skin | |
| JP2000143527A (en) | Hyaluronic acid production promoter and skin preparation for external use containing the same | |
| JP2000109420A (en) | Cosmetic against aging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040105 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |